Table 1. Drug resistance of the specific targeted HSV-1 mutants.
| Amino acid substitution | Mean EC50 in μM ± SD |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACV |
PCV |
BVDU |
FOS |
|||||||||
| HSV-1 mutant* | HSV-1 MI | HSV-1 (17+) | HSV-1 mutant | HSV-1 MI | HSV-1 (17+) | HSV-1 mutant | HSV-1 MI | HSV-1 (17+) | HSV-1 mutant | HSV-1 MI | HSV-1 (17+) | |
| R41H | <0.29** (1.56 ± 0.30) | 0.61 ± 0.20 | <1.11** | 2.67 ± 1.14 | 2.50 ± 0.08 | 2.29 ± 0.62 | <0.19** | <0.59** | <0.19** | 145.54 ± 54.25 | 80.70 ± 90.00 | 64.02 ± 33.14 |
| G61A | 46.13 ± 27.32 (>35.2**) | <0.54** | <1.11** | 42.40 ± 35.60 | 1.49 ± 0.93 | 1.68 ± 1.24 | 3.06 ± 2.22 | <0.59** | <0.19** | 124.75 ± 50.25 | 210.35 ± 19.65 | 42.84 ± 11.96 |
| P84L | 34.60 ± 3.90 (21.90 ± 12.15) | 1.52 ± 0.28 | <0.28** | 20.41 ± 3.92 | 2.50 ± 0.09 | 2.29 ± 0.62 | 44.95 ± 41.54 | <0.59** | <0.19** | 281.25 ± 16.75 | 180.69 ± 60.10 | 64.02 ± 33.14 |
| R106H | <0.58** (0.90 ± 0.22) | <0.54** | <1.11** | <1.38** | <1.33** | 1.64 ± 1.28 | <0.19** | 0.59 ± 0.33 | <0.19** | 131.50 ± 38.50 | 86.60 ± 4.10 | 43.44 ± 12.56 |
| A118V | <0.28** (1.10 ± 0.30) | 0.61 ± 0.20 | <1.11** | 1.77 ± 0.65 | 1.87 ± 0.55 | 1.76 ± 1.16 | <0.19** | <0.59** | <0.19** | 211.60 ± 31.60 | 167.12 ± 76.42 | 44.34 ± 13.46 |
| L139V | <0.28** (0.72 ± 0.38) | <0.75** | <0.28** | 0.82 ± 0.05 | 3.05 ± 0.46 | 1.81 ± 0.14 | <0.19** | 0.19 ± 0 | <0.19** | 92.19 ± 1.69 | 190.85 ± 59.85 | 74.13 ± 18.69 |
| K219T | <0.28** (1.36 ± 0.81) | <0.75** | <0.28** | <0.88** | <1.87** | 1.15 ± 0.79 | <0.19** | 0.19 ± 0 | <0.19** | 114.90 ± 77.10 | 202.00 ± 53.00 | 71.79 ± 21.21 |
| S276R | <0.28** (1.06 ± 0.81) | <0.75** | <0.28** | 0.96 ± 0.40 | 2.03 ± 1.47 | 1.19 ± 0.75 | <0.19** | <0.19** | <0.19** | 199.50 ± 57.50 | 115.75 ± 33.25 | 53.29 ± 2.71 |
| L298R | <0.29** (2.21 ± 0.94) | 0.82 ± 0.41 | <0.28** | 2.07 ± 0.53 | 3.05 ± 0.46 | 1.81 ± 0.14 | <0.19** | 0.19 ± 0 | <0.19** | 135.50 ± 53.90 | 196.27 ± 47.27 | 54.19 ± 3.61 |
| S345P | <0.28** (1.50 ± 0.68) | 0.82 ± 0.41 | <0.28** | 1.07 ± 0.18 | 3.05 ± 0.46 | 1.81 ± 0.14 | <0.19** | <0.19** | <0.19** | 92.37 ± 42.27 | 196.27 ± 47.27 | 54.29 ± 3.67 |
| V348I | <0.28** (1.67 ± 0.92) | 0.82 ± 0.41 | <0.28** | 1.27 ± 0.15 | 2.41 ± 1.09 | 1.27 ± 0.67 | <0.19** | 0.19 ± 0 | <0.19** | 84.80 ± 7.30 | 130.00 ± 19.00 | 53.09 ± 2.50 |
Mean effective concentration 50% (EC50) values plus standard deviation (SD) of aciclovir (ACV), penciclovir (PCV), bromovinyldeoxyuridine (BVDU), and foscarnet (FOS) in μM on the basis of triplicates after phenotypic testing HSV-1 mutants by cytopathic effect inhibition assay in comparison with susceptible control strains HSV-1 MI and HSV-1 (17+). Values related to resistance are in bold.
Values in brackets refer to calculation from relative fluorescence unit (RFU).
**Calculation of SD not possible.